Abingworth lines up $315M to bet on a new generation of transatlantic biotechs
A prominent UK-based biotech fund has reloaded with a $315 million raise for its next round of bets in the field. Abingworth, which has been …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
